Abstract
Objectives: To evaluate the efficacy and safety of TS1-Cisplatin regimen in the
first - line treatment of metastatic gastric cancer patients.
Methods: 38 eligible patients were treated with TS1-cisplatin at Hanoi Medical
University Hospital from January 2018 to December 2021.
Results: Mean age was 57.4. Male: female ratio = 3.2:1. Most patients had good
performance status (PS 0 or PS 1 - 84.2%). Most received dose rate from 85% to 100%
of standard dose (78.9%). After six cycles, complete response rate was 13.2%, partial
response rate was 42.1%. The median progression - free survival was 5.7 months. The
median overall survival was 13.5 months. Neutropenia was the most common adverse
event (52.6%), of which 13.1% was in grade 3 - 4. Diarrhea accounted for 36.8%, only
one of which was in grade 3 (2.6%). Only one patient had hand - foot syndrome (2.6%).
Conclusion: TS1-Cisplatin regimen in metastatic gastric cancer had a good
response rate while being safe and tolerable.
References
Sung H, Ferlay J, Siegel RL et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2021;71(3): 209-249.
Kobayakawa M, Kojima Y. Tegafur/ gimeracil/ oteracil (S- 1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies. Onco Tagets and Ther. 2011;4:193-201
Wagner AD, Grothe W, Haerting J, Kleber G et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006; 24(18): 2903-2909.
Koizumi W, Narahara H et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9: 215-221.
Boku N, Yamamoto S, Fukuda H et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. The Lancet Oncology. 2009;10(11): 1063-1069.
Ajani JA, Buyse M, Lichinitser M et al. Combination of Cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with Cisplatin/5- fluorouracil in the First-Line Andvanced Gastric Cancer Study. European Journal of Cancer. 2013;49:3616-3624.
Khanh Ha Nguyen. Evaluating the treatment results of TCX regimen in recurrent or metastatic gastric cancer. Medical Thesis. 2019. Hanoi Medical University.
Nhu Hanh To. Evaluating the treatment results of EOX regimen in inoperable advanced gastric cancer. Medical Thesis. 2012. Hanoi Medical University.
Van Hung Nguyen, Hong Thang Vu, Hai Dang Do, et al. Evaluating the treatment results of FOLFIRI regimen in advanced gastric cancer. Vietnam Medical Journal. 2017;459.
Li Y, Qiu M, Xu J. S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study. Oncotarget. 2015;6(33):35107-35115.
Boku N, Yamamoto S, Fukuda H et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomized phase 3 study. The Lancet Oncology. 2009;10(11): 1063-1069.
He M, Wu W, Wang F et al. S-1-Based Chemotherapy versus Capecitabine-Based Chemotherapy as First-Line Treatment for Advanced Gastric Carcinoma: A Meta-Analysis. PLoS ONE. 2013;8(12): e8279
| Published | 25-03-2022 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | No. 78 (2022) | |
| Section | Original article | |
| DOI | 10.38103/jcmhch.78.3 | |
| Keywords | Advanced gastric cancer, TS1, cisplatin Advanced gastric cancer, TS1, cisplatin |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2022 Journal of Clinical Medicine Hue Central Hospital